Advertisement
Canada markets closed

  • S&P/TSX

    24,224.90
    +152.39 (+0.63%)
     

  • S&P 500

    5,792.04
    +40.91 (+0.71%)
     

  • DOW

    42,512.00
    +431.63 (+1.03%)
     

  • CAD/USD

    0.7294
    0.0000 (-0.00%)
     

  • CRUDE OIL

    73.43
    +0.19 (+0.26%)
     

  • Bitcoin CAD

    83,167.86
    -2,003.82 (-2.35%)
     

  • XRP CAD

    0.72
    -0.01 (-0.95%)
     

  • GOLD FUTURES

    2,626.50
    +0.50 (+0.02%)
     

  • RUSSELL 2000

    2,200.59
    +5.60 (+0.26%)
     

  • 10-Yr Bond

    4.0670
    +0.0340 (+0.84%)
     

  • NASDAQ futures

    20,445.50
    -18.00 (-0.09%)
     

  • VOLATILITY

    20.86
    -0.56 (-2.61%)
     

  • FTSE

    8,243.74
    +53.13 (+0.65%)
     

  • NIKKEI 225

    39,277.96
    +340.42 (+0.87%)
     

  • CAD/EUR

    0.6663
    -0.0001 (-0.02%)
     
MARKETS LIVE BLOG:

S&P 500, DOW NOTCH FRESH RECORDS AS KEY U.S. CPI REPORT LOOMS

Minutes favour a more hawkish stance from Fed in November: Strategist

IGM Biosciences (IGMS) Soars 32.7%: Is Further Upside Left in the Stock?

Zacks Equity Research
·2 min read

IGM Biosciences, Inc. (IGMS) shares ended the last trading session 32.7% higher at $9.30. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 13.2% loss over the past four weeks.

The sudden soaring of the stock can be attributed to the positive investor mindset regarding the potential of IGM Biosciences' pipeline of Immunoglobin M antibody-based candidates to treat patients with cancer and autoimmune and inflammatory diseases.

This company is expected to post quarterly earnings of $0.03 per share in its upcoming report, which represents a year-over-year change of +102.1%. Revenues are expected to be $51.75 million, up 11400% from the year-ago quarter.

While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For IGM Biosciences, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on IGMS going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

IGM Biosciences is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Agenus (AGEN), finished the last trading session 0.6% higher at $15.39. AGEN has returned -9.6% over the past month.

Agenus' consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$2.04. Compared to the company's year-ago EPS, this represents a change of +49%. Agenus currently boasts a Zacks Rank of #3 (Hold).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

IGM Biosciences, Inc. (IGMS) : Free Stock Analysis Report

Agenus Inc. (AGEN) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research